vs
BankUnited, Inc.（BKU）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
BankUnited, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$288.2M vs $207.3M），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 9.0%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.2%）
BankUnited, Inc.是美国国民银行BankUnited, N.A.的控股公司，成立于1984年，总部位于佛罗里达州迈阿密莱克斯。业务覆盖佛罗里达州、佐治亚州亚特兰大及周边、得克萨斯州达拉斯、新泽西州莫里斯敦、北卡罗来纳州夏洛特，以及纽约大都会区，还通过全国性平台提供部分商业贷款和存款产品，截至2025年12月31日总资产达350亿美元。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BKU vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $288.2M | $207.3M |
| 净利润 | — | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 31.2% | -54.7% |
| 净利率 | — | -62.0% |
| 营收同比 | 9.0% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.89 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $288.2M | $207.3M | ||
| Q3 25 | $275.7M | $159.9M | ||
| Q2 25 | $273.9M | $166.5M | ||
| Q1 25 | $255.4M | $139.3M | ||
| Q4 24 | $264.5M | $164.6M | ||
| Q3 24 | $257.0M | $139.5M | ||
| Q2 24 | $250.2M | $147.0M | ||
| Q1 24 | $241.7M | $108.8M |
| Q4 25 | — | $-128.6M | ||
| Q3 25 | $71.9M | $-180.4M | ||
| Q2 25 | $68.8M | $-115.0M | ||
| Q1 25 | $58.5M | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | $61.5M | $-133.5M | ||
| Q2 24 | $53.7M | $-131.6M | ||
| Q1 24 | $48.0M | $-170.7M |
| Q4 25 | 31.2% | -54.7% | ||
| Q3 25 | 35.5% | -106.9% | ||
| Q2 25 | 34.3% | -64.8% | ||
| Q1 25 | 31.4% | -102.6% | ||
| Q4 24 | 35.2% | -74.3% | ||
| Q3 24 | 32.4% | -94.6% | ||
| Q2 24 | 29.2% | -79.1% | ||
| Q1 24 | 27.8% | -151.9% |
| Q4 25 | — | -62.0% | ||
| Q3 25 | 26.1% | -112.8% | ||
| Q2 25 | 25.1% | -69.0% | ||
| Q1 25 | 22.9% | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | 23.9% | -95.7% | ||
| Q2 24 | 21.5% | -89.5% | ||
| Q1 24 | 19.8% | -156.8% |
| Q4 25 | $0.89 | $-1.28 | ||
| Q3 25 | $0.95 | $-1.81 | ||
| Q2 25 | $0.91 | $-1.17 | ||
| Q1 25 | $0.78 | $-1.57 | ||
| Q4 24 | $0.91 | $-1.34 | ||
| Q3 24 | $0.81 | $-1.40 | ||
| Q2 24 | $0.72 | $-1.52 | ||
| Q1 24 | $0.64 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $217.8M | $421.0M |
| 总债务越低越好 | $319.7M | — |
| 股东权益账面价值 | $3.1B | $-80.0M |
| 总资产 | $35.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.10× | — |
8季度趋势，按日历期对齐
| Q4 25 | $217.8M | $421.0M | ||
| Q3 25 | $559.5M | $202.5M | ||
| Q2 25 | $801.3M | $176.3M | ||
| Q1 25 | $443.7M | $127.1M | ||
| Q4 24 | $491.1M | $174.0M | ||
| Q3 24 | $889.9M | $150.6M | ||
| Q2 24 | $433.5M | $480.7M | ||
| Q1 24 | $421.2M | $112.3M |
| Q4 25 | $319.7M | — | ||
| Q3 25 | $320.4M | — | ||
| Q2 25 | $708.9M | — | ||
| Q1 25 | $709.1M | — | ||
| Q4 24 | $708.6M | — | ||
| Q3 24 | $708.7M | — | ||
| Q2 24 | $708.8M | — | ||
| Q1 24 | $709.0M | — |
| Q4 25 | $3.1B | $-80.0M | ||
| Q3 25 | $3.0B | $9.2M | ||
| Q2 25 | $3.0B | $151.3M | ||
| Q1 25 | $2.9B | $144.2M | ||
| Q4 24 | $2.8B | $255.0M | ||
| Q3 24 | $2.8B | $346.8M | ||
| Q2 24 | $2.7B | $432.4M | ||
| Q1 24 | $2.6B | $140.3M |
| Q4 25 | $35.0B | $1.5B | ||
| Q3 25 | $35.1B | $1.2B | ||
| Q2 25 | $35.5B | $1.3B | ||
| Q1 25 | $34.8B | $1.3B | ||
| Q4 24 | $35.2B | $1.5B | ||
| Q3 24 | $35.8B | $1.5B | ||
| Q2 24 | $35.4B | $1.6B | ||
| Q1 24 | $35.1B | $1.3B |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 0.24× | — | ||
| Q1 25 | 0.24× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | 0.26× | — | ||
| Q1 24 | 0.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $358.6M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $358.6M | $-99.8M | ||
| Q3 25 | $99.7M | $-91.4M | ||
| Q2 25 | $117.6M | $-108.3M | ||
| Q1 25 | $16.4M | $-166.5M | ||
| Q4 24 | $433.8M | $-79.3M | ||
| Q3 24 | $46.1M | $-67.0M | ||
| Q2 24 | $135.7M | $-77.0M | ||
| Q1 24 | $66.5M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.75× | — | ||
| Q2 24 | 2.53× | — | ||
| Q1 24 | 1.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BKU
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
